HC Wainwright restated their buy rating on shares of AzurRx BioPharma (NASDAQ:AZRX) in a report issued on Wednesday morning, AnalystRatings.com reports. The firm currently has a $6.00 price objective on the stock.
“Our price target is derived from a market value of the firm at $199M, which includes a discounted cash flow- based asset value of $201M for MS1819, using a 15% discount rate and 2% terminal growth rate, excluding $2M convertible debt, with 50% probability of success. Risks include, but are not limited to: (1) failure of MS1819 in clinical trials; (2) failure of MS1819 to secure regulatory approval; (3) failure of MS1819 to achieve commercial success due to reimbursement, penetration rate, and/or competition; and (4) dilution risk.”,” HC Wainwright’s analyst wrote.
AZRX has been the subject of several other research reports. National Securities started coverage on AzurRx BioPharma in a research note on Tuesday, June 11th. They set a buy rating and a $9.00 price objective for the company. ValuEngine raised AzurRx BioPharma from a hold rating to a buy rating in a research note on Thursday, August 1st. Finally, Maxim Group reissued a buy rating and set a $5.00 price objective on shares of AzurRx BioPharma in a research note on Wednesday, April 24th. Seven investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and a consensus target price of $7.42.
AzurRx BioPharma (NASDAQ:AZRX) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.08). Equities research analysts anticipate that AzurRx BioPharma will post -0.78 earnings per share for the current year.
Large investors have recently bought and sold shares of the stock. Royal Bank of Canada bought a new position in shares of AzurRx BioPharma during the 2nd quarter valued at about $48,000. Vanguard Group Inc. lifted its holdings in shares of AzurRx BioPharma by 255.0% during the 2nd quarter. Vanguard Group Inc. now owns 260,306 shares of the company’s stock valued at $443,000 after purchasing an additional 186,985 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of AzurRx BioPharma by 57.6% during the 2nd quarter. BlackRock Inc. now owns 42,313 shares of the company’s stock valued at $72,000 after purchasing an additional 15,463 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of AzurRx BioPharma during the 2nd quarter valued at about $57,000. Finally, Regentatlantic Capital LLC bought a new position in shares of AzurRx BioPharma during the 1st quarter valued at about $48,000. 10.59% of the stock is owned by institutional investors.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Featured Story: Why is total return important?
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.